Cite
HARVARD Citation
Ruel, T. et al. (2022). Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial. Lancet. 9 (5), pp. e332-e340. [Online].